Q4 results: Biomet recon slump suggests rebound hopes premature
This article was originally published in Clinica
Biomet’s modest fourth-quarter hip and knee sales growth could indicate a deceleration in the overall large joint reconstruction markets, according to analysts. Earlier this year, a run of decent results from players including Biomet itself raised hopes of a turnaround in the reconstructive market – but it now seems these may have been premature.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.